Compare BlackRock TCP Capital Corp (TCPC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackRock TCP Capital Corp vs State Street SPDR S&P Biotech ETF — how do they compare? BlackRock TCP Capital Corp trades at $3.24 (market cap $270.17M), while State Street SPDR S&P Biotech ETF trades at $154.4. The key difference: BlackRock TCP Capital Corp pays a 26.09% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, BlackRock TCP Capital Corp nearer its low. Which is the better fit depends on your goals.
| TCPC | XBI | |
|---|---|---|
Market Cap | $270.17M | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $7.64 | $164.28 |
52-Week Low | $3.14 | $85.16 |
Dividend Yield | 26.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TCPC trades at $3.21, down 3.02% today, with a bearish technical signal and negative revenue trends. The company reported a net loss of $88.93M in 2025, though it maintains a 112% net income margin due to accounting adjustments. Recent news includes a Zacks upgrade to Buy and an upcoming Q2 2026 earnings report on August 6, 2026.
Outlook remains cautious with mixed analyst sentiment (30.77% Buy) and ongoing legal scrutiny. The stock's low P/B of 0.49 suggests potential value, but persistent losses and negative cash flow pose significant risks. Dividend sustainability is a key concern amid financial pressures.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
